AAIPharma Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Wilmington NC United States (1979)
Status: Acquired by Alcami (2013)

Organization Overview

First Clinical Trial
2001
NCT01888328
First Marketed Drug
1979
acetylsalicylic acid (aspirin)
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AAI | AAI, 6101 Quadrangle Drive, Chapel Hill, NC 27514 | AAI Clinic | AAI Clinic (AAIPharma Inc.) | AAI Deutschland GmbH & Co. KG | AAIOncology | aaiPharma | aai Pharma | AAIPharma | AAIPharma Deutschland GmbH & Co. KG | AAIPharma Inc., AAI Clinic | AAIPHARMA LLC | AAI Scientific Cultural Services Ltd (AAISCS)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 1)

Exocrine Pancreatic Insufficiency (Phase 2)

Failure to Thrive (Phase 1)

Intermittent Claudication (Phase 1)

Leukemia (Phase 2)

Malnutrition (Phase 1)

Neoplasms (Phase 1)

Pain, Postoperative (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 28
  • # of Trial APIs: 21